menu
    • menu

    Company profile for Satsuma Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers. STS101 is Satsuma's lead product candidate. STS101 is a potential best-in-class therapy for migraine that combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and drug delivery device technologies created and developed over the pas...
    Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers. STS101 is Satsuma's lead product candidate. STS101 is a potential best-in-class therapy for migraine that combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and drug delivery device technologies created and developed over the past 15 years by SNBL that enable rapid absorption with high bioavailability of drugs delivered via the nose.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Satsuma PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Oyster Point Boulevard, Suite 221, South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.satsumarx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/satsuma-pharmaceuticals-inc.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Satsuma Pharma & SNBL Publish STS101 Satisfaction Study
    Satsuma Pharma & SNBL Publish STS101 Satisfaction Study

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumi-in-headache-302604636.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share
    Segal Trials Helps Atzumi Get FDA Nod for Migraine Treatment
    Segal Trials Helps Atzumi Get FDA Nod for Migraine Treatment

    24 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250623226289/en/Segal-Trials-Investigator-Dr.-Olga-Lapeyra-Contributes-to-Pivotal-Migraine-Study-Leading-to-FDA-Approval-of-Atzumi

    BUSINESSWIRE
    24 Jun 2025
    Share Share
    Satsuma Pharmaceuticals and SNBL to Present Four Abstracts at AHS
    Satsuma Pharmaceuticals and SNBL to Present Four Abstracts at AHS

    19 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-societys-67th-annual-scientific-meeting-302485616.html

    PR NEWSWIRE
    19 Jun 2025
    Share Share
    Satsuma Pharma Announces FDA Approval for Atzumi Nasal Powder
    Satsuma Pharma Announces FDA Approval for Atzumi Nasal Powder

    01 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-announces-us-fda-approval-for-atzumi-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-302443234.html

    PR NEWSWIRE
    01 May 2025
    Share Share
    Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine
    Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine

    26 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura-302316089.html

    PR NEWSWIRE
    26 Nov 2024
    Share Share
    Satsuma Resubmits NDA for STS101 (Migraine Treatment)
    Satsuma Resubmits NDA for STS101 (Migraine Treatment)

    30 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura-302292154.html

    PR NEWSWIRE
    30 Oct 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search